We are live on ! Find out more
NERV icon

Minerva Neurosciences

71 hedge funds and large institutions have $205M invested in Minerva Neurosciences in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 26 increasing their positions, 20 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 20

0.1% more ownership

Funds ownership: 8.88%8.98% (+0.1%)

9% less funds holding

Funds holding: 7871 (-7)

18% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 11

29% less capital invested

Capital invested by funds: $290M → $205M (-$85.2M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
71
Holders Change
-7
Holders Change %
-8.97%
% of All Funds
1.77%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
9
Increased
26
Reduced
20
Closed
11
Calls
$83K
Puts
Net Calls
+$83K
Net Calls Change
+$83K
Name Holding Trade Value Shares
Change
Change in
Stake
Norges Bank
76
Norges Bank
Norway
-$839K -8,929 Closed
Susquehanna International Group
77
Susquehanna International Group
Pennsylvania
-$492K -6,338 Closed
M&T Bank
78
M&T Bank
New York
-$289K -3,077 Closed
OAM
79
Oxford Asset Management
United Kingdom
-$218K -2,322 Closed
MLICM
80
Metropolitan Life Insurance Company (MetLife)
New York
-$189K -2,015 Closed
Squarepoint
81
Squarepoint
New York
-$122K -1,296 Closed
Creative Planning
82
Creative Planning
Kansas
-$33K -346 Closed

NERV Hedge Fund Activity: Q1 2017 in Review

71 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Minerva Neurosciences (NERV) for Q1 2017, worth a combined $205M — down 29% from $290M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of NERV and 9 opened new positions — a net loss of 2 holders — while 20 trimmed existing stakes and 26 added.

The largest buyer was BlackRock, adding an estimated $14.7M. The largest seller was Marshall Wace, exiting entirely with an estimated $5.2M sold.

  • 71 institutional investors held Minerva Neurosciences (NERV) as of Q1 2017, down from 78 in Q4 2016.
  • Funds reported $205M of Minerva Neurosciences stock for Q1 2017, down 29% quarter-over-quarter.
  • 9 funds opened new Minerva Neurosciences positions in Q1 2017 and 11 closed out, a net change of -2 holders.
  • The largest Minerva Neurosciences buyer in Q1 2017 was BlackRock, an estimated $14.7M added.
  • The largest Minerva Neurosciences seller in Q1 2017 was Marshall Wace, an estimated $5.2M sold.

Based on aggregated 13F filings for Q1 2017.